bristol-myers squibb

The S&P 500 soared 12% during the first three months of 2012, and the tech-heavy Nasdaq managed a nearly 19% spurt. Those are good numbers even for a whole year -- but these seven investments beat the indexes by huge margins.

Bristol-Myers Squibb recalled one lot of its blood thinner medicine Coumadin after tests showed the tablets could be more potent than the dosage, said the U.S. Food and Drug Administration (FDA). Coumadin -- also known as warfarin sodium -- is prescribed to treat and prevent blood clots, and to...

The pharmaceutical industry is ready to fall off a cliff -- a "patent cliff." Over the next few years, some of the world's most popular and lucrative medicines will go off patent, and generic competition will siphon an estimated quarter of a trillion dollars from drugmakers' bottom lines.

Big Pharma didn't rest Thursday, with Celgene, Sanofi-Aventis and AstraZeneca among the big names reporting earnings. A deal between Stryker and Boston Scientific and Sanofi and BMP Sunstone also made the headlines, as did some hiring from Teva. Bristol-Myers Squibb received the anticipated new approval for one of its cancer drugs. But it was Celgene that led drug stocks higher.

Bristol-Myers Squibb, which sells blood thinner Plavix, today reported better-than-expected third quarter earnings, mainly due to cost cuts. Revenue, however, fell short of expectations, and shares are down in trading Tuesday.

Pfizer and Bristol-Myers Squibb said on Thursday that they've decided to halt a clinical trial several months early because data so far suggested the experimental drug apixaban was more effective than aspirin in preventing strokes among patients.

Citigroup Inc. (C) said Monday it is repaying $20 billion in bailout money of the $45 billion it received from the Treasury Department. Citi doesn't need to pay the remaining $25 billion, as the government has converted it into a 34% stake in the bank. Paying back the TARP money would help Citi at...

It seems that when it comes to Aranesp, its blockbuster anemia drug, Amgen (AMGN) just can't catch a break, nor for that matter, create one. Recently, Amgen was hit with a double whammy -- a lawsuit and an unfavorable study of the drug. On Tuesday, yet another study confirmed that cancer patients...